133 related articles for article (PubMed ID: 36093869)
1. Prognostic factors in primary central nervous system lymphoma.
Morales-Martinez A; Nichelli L; Hernandez-Verdin I; Houillier C; Alentorn A; Hoang-Xuan K
Curr Opin Oncol; 2022 Nov; 34(6):676-684. PubMed ID: 36093869
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study.
Li J; Tang X; Luo X; Liu L; Li D; Yang L
Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system.
Sasagawa Y; Akai T; Tachibana O; Iizuka H
J Neurooncol; 2015 Jan; 121(1):177-83. PubMed ID: 25258254
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of Interim 11C-Methionine PET/CT in Primary Central Nervous System Lymphoma.
Ahn SY; Kwon SY; Jung SH; Ahn JS; Yoo SW; Min JJ; Bom HS; Ki SY; Kim HJ; Lee JJ; Song SY; Yang DH
Clin Nucl Med; 2018 Aug; 43(8):e259-e264. PubMed ID: 29877882
[TBL] [Abstract][Full Text] [Related]
5. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients.
Nguyen-Them L; Costopoulos M; Tanguy ML; Houillier C; Choquet S; Benanni H; Elias-Shamieh R; Armand M; Faivre G; Glaisner S; Malak S; Vargaftig J; Hoang-Xuan K; Ahle G; Touitou V; Cassoux N; Davi F; Merle-Béral H; Le Garff-Tavernier M; Soussain C;
Eur J Cancer; 2016 Jul; 61():69-76. PubMed ID: 27156226
[TBL] [Abstract][Full Text] [Related]
6. Primary central nervous system lymphoma: advances in its pathogenesis, molecular markers and targeted therapies.
Hernández-Verdin I; Morales-Martínez A; Hoang-Xuan K; Alentorn A
Curr Opin Neurol; 2022 Dec; 35(6):779-786. PubMed ID: 36367044
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma.
Hatzoglou V; Oh JH; Buck O; Lin X; Lee M; Shukla-Dave A; Young RJ; Peck KK; Vachha B; Holodny AI; Grommes C
J Neurooncol; 2018 Nov; 140(2):351-358. PubMed ID: 30073640
[TBL] [Abstract][Full Text] [Related]
8. Can metabolic tumor parameters on primary staging
Okuyucu K; Alagoz E; Ince S; Ozaydin S; Arslan N
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):9-14. PubMed ID: 28733137
[TBL] [Abstract][Full Text] [Related]
9. Changes in cerebrospinal fluid interleukin-10 levels display better performance in predicting disease relapse than conventional magnetic resonance imaging in primary central nervous system lymphoma.
Zhang Y; Zou D; Yin J; Zhang L; Zhang X; Wang W; Zhang M; Zhou D; Zhang W
BMC Cancer; 2021 Feb; 21(1):183. PubMed ID: 33618687
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment Hemoglobin as an Independent Prognostic Factor in Primary Central Nervous System Lymphomas.
Le M; Garcilazo Y; Ibáñez-Juliá MJ; Younan N; Royer-Perron L; Benazra M; Mokhtari K; Houillier C; Hoang-Xuan K; Alentorn A
Oncologist; 2019 Sep; 24(9):e898-e904. PubMed ID: 30867243
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL).
Sasayama T; Nakamizo S; Nishihara M; Kawamura A; Tanaka H; Mizukawa K; Miyake S; Taniguchi M; Hosoda K; Kohmura E
Neuro Oncol; 2012 Mar; 14(3):368-80. PubMed ID: 22156547
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal Fluid IL-10 and IL-10/IL-6 as Accurate Diagnostic Biomarkers for Primary Central Nervous System Large B-cell Lymphoma.
Song Y; Zhang W; Zhang L; Wu W; Zhang Y; Han X; Yang C; Zhang L; Zhou D
Sci Rep; 2016 Dec; 6():38671. PubMed ID: 27924864
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory brain lesions preceding primary central nervous system lymphoma: a case report and genetic analysis.
XiaoHong Z; Shuo Y; GeHong D; AnChao Y; Ce W; YunYun D; Can W; SiJie H; Feng C; WenBin L
Neurol Sci; 2023 May; 44(5):1555-1561. PubMed ID: 36599976
[TBL] [Abstract][Full Text] [Related]
14. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: A systematic review and meta-analysis.
Zou Y; Tong J; Leng H; Jiang J; Pan M; Chen Z
Oncotarget; 2017 Jun; 8(25):41518-41528. PubMed ID: 28514747
[TBL] [Abstract][Full Text] [Related]
16. Current strategies in the diagnosis of diffuse large B-cell lymphoma of the central nervous system.
Baraniskin A; Deckert M; Schulte-Altedorneburg G; Schlegel U; Schroers R
Br J Haematol; 2012 Feb; 156(4):421-32. PubMed ID: 22077417
[TBL] [Abstract][Full Text] [Related]
17. What is the Best Preoperative Quantitative Indicator to Differentiate Primary Central Nervous System Lymphoma from Glioblastoma?
Inoue A; Matsumoto S; Ohnishi T; Miyazaki Y; Kinnami S; Kanno K; Honda T; Kurata M; Taniwaki M; Kusakabe K; Suehiro S; Yamashita D; Shigekawa S; Watanabe H; Kitazawa R; Kunieda T
World Neurosurg; 2023 Apr; 172():e517-e523. PubMed ID: 36690204
[TBL] [Abstract][Full Text] [Related]
18. Molecular and clinical diversity in primary central nervous system lymphoma.
Hernández-Verdin I; Kirasic E; Wienand K; Mokhtari K; Eimer S; Loiseau H; Rousseau A; Paillassa J; Ahle G; Lerintiu F; Uro-Coste E; Oberic L; Figarella-Branger D; Chinot O; Gauchotte G; Taillandier L; Marolleau JP; Polivka M; Adam C; Ursu R; Schmitt A; Barillot N; Nichelli L; Lozano-Sánchez F; Ibañez-Juliá MJ; Peyre M; Mathon B; Abada Y; Charlotte F; Davi F; Stewart C; de Reyniès A; Choquet S; Soussain C; Houillier C; Chapuy B; Hoang-Xuan K; Alentorn A
Ann Oncol; 2023 Feb; 34(2):186-199. PubMed ID: 36402300
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review).
Liu Y; Yao Q; Zhang F
Int J Oncol; 2021 Mar; 58(3):371-387. PubMed ID: 33650642
[TBL] [Abstract][Full Text] [Related]
20. [Clinical features and treatment outcomes in primary central nervous system lymphoma: a descriptive analysis of 62 patients].
Ge Y; Lin XT; Luo DL; Zhang F; Xu J; Li Z; Liu YH
Zhonghua Bing Li Xue Za Zhi; 2019 Nov; 48(11):861-866. PubMed ID: 31775435
[No Abstract] [Full Text] [Related]
[Next] [New Search]
